Gilead Sciences exercised its option to license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets.
Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
FDA approval for Enhertu as a first-line breast cancer treatment is important because many patients with HER2-positive cancer do not live long enough to receive a second line of therapy. In Enhertu’s pivotal study in this setting, the HER2-targeting ADC helped patients live more than three years without disease progression or death.
Hackensack Meridian Health launched a clinical trial with Israeli startup SpotitEarly, which is developing a cancer test that combines AI with trained dogs to analyze patients’ breath. The study aims to validate this noninvasive approach alongside traditional screenings, potentially enabling earlier and more accessible cancer detection.
If we truly believe in treating the whole patient, we must recognize that survival is not the only measure of success. Preserving a woman’s sense of self, her dignity, her identity, her autonomy is just as essential.
Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug combinations to treat cancer. The deal calls for the two companies to share in the development of BioNTech’s drug and co-commercialize the asset globally.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The women’s health market offers enormous potential for investment and innovation. While challenges related to systemic inequalities remain, progress in venture capital funding is encouraging. Likewise, the overall increase in patent filings related to breast cancer, endometriosis, and other conditions appears to reflect a growing interest in women’s health.
Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy.
AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer.
Our goal should be to make lymphedema a preventable aspect of cancer survivorship or at a minimum, manageable, rather than a debilitating aftereffect that diminishes patients' quality of life.
How to turn analytics into actual policy outcomes.
We should use AI to develop recommendations for breast cancer screening protocols based on quantified risk, factoring in family history, ethnicity, genetics, and density, et al. – and then support the use of powerful new imaging AI technologies for those cases that demand a deeper look.
Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones.
March is Lymphedema Awareness Month, and today there are more options than ever to help prevent this challenging and all too common complication associated with breast cancer treatment.
While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.
The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.